Unresolver problem of calcium in phosphate-binding therapy of bone-mineral metabolism dis-turbances in patients with chronic kidney disease on program hemodialysis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Risk factors and pathogenesis of vascular calcification in chronic kidney disease are discussed. Therapeutic approaches to correction of bone-mineral metabolism disturbances in chronic kidney disease are reviewed with special attention to comparison of different phosphate-binders.

Full Text

Restricted Access

About the authors

S. E Khoroshilov

References

  1. Levey A.S., Coresh J. Chronic kidney disease. Lancet. 2012; 379:165-80.
  2. U.S. Renal Data System: USRDS 2002 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
  3. Шутов Е.В. Нутритивный статус у больных с хронической почечной недостаточностью. Нефрология и диализ. 2008; № 3-4 (Т. 10): 199-207.
  4. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2009 гг. (отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ. 2011; 13(3): 150-264.
  5. Земченков А. Ю., Томилина Н. А. «К/ДОКИ» обращается к истокам хронической почечной недостаточности (О новом разделе Рекомендаций K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек). Нефрология и диализ.2004; № 3 (Т. 6): 204-220.
  6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003; 42(suppl3): 1-202.
  7. The treatment of heart failure. The Task Force of Working Group on Heart Failure of European Society of Cardiology. Eur Heart J. 1997; 18: 736-753.
  8. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145-153.
  9. Хорошилов С.Е., Никитин А.В., Очиченко Т.Ю. Опыт лечения тяжелых нарушений фосфорно-кальциевого обмена при терминальной почечной недостаточности с использованием цинакалцета. Лечащий Врач. 2010; 1:2-7.
  10. Goodman W.G., Goldin J., Kuizon B.D. Coronary-artery calcification in young adults with end-stage renal disease who are undergouing dialysis. N Engl J Med. May 18 2000; 342(20): 1478-1483.
  11. Гранкин В.И., Новосельцев И.Л., Новицкий Л.В. и др. Диагностика и лечение нарушений фосфорно-кальциевого обмена и вторичного гиперпаратиреоза у больных с терминальной почечной недостаточностью: Методические указания. М., ГВКГ им. Н.Н. Бурденко. 2005.
  12. Ермоленко В.М. Фосфорно-кальциевый обмен и почки. Нефрология:
  13. Новиков А.И. Современный взгляд на патогенез гиперпаратиреоза при почечной недостаточности как на проблему роста отдельных клонов паращитовидной железы. Практическая нефрология. 1998; 2: 27-36.
  14. Qunibi W. Y., Goldin J., Kuizon B.D. Coronary calcification in patients with endstage renal disease: A century-old phenomenon. Kidney Int Suppl. Dec 2002(82): 73-80.
  15. Jono S., McKee M.D., Murry C.E. et al. Phosphate regulation of vascular smooth muscle cell calcif cation. Circ Res. 2000; 87: E10-17.
  16. Levin A., Bakris G.L., Molitch M. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71(1): 31-38.
  17. Miyamoto K., Tatsumi S., Segawa H. et al. Regulation of PiT-1, a sodium-dependent phosphate co-transporter in rat parathyroid glands. Nephrol Dial Transplant. 1999; 14 (Suppl 1): 73-75.
  18. Drueke T.B. Foreword: Extraskeletal calcification in patients with chronic renal failure. Nephrol. Dial. Transplant. 2002; 17: 330-331.
  19. Ortiz-Capisano M.C., Ortiz P.A., Garvin J.L. Expression and functional calcium-sensing receptor in juxtaglomerular cells. Hypertension. 2007; 50(4): 737-743.
  20. Bricker N.S. On the pathogenesis of the uremic state. An exposition of the «Trade-off hypothesis». N.Engl. J. Med. 1972; 286; 1093-1099.
  21. Block G.A., Hulbert-Shearon T.E., Levin N. W. et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607-617.
  22. Brown E.M. Mechanism underlying the regulation of the parathyroid hormone secretion in vivo and in vitro. Curr. Opinion. Nephrol. Hypertension. 1993; 2: 541-551.
  23. Kuhlman M. Phosphate elimination in vodalities of hemodialysis and peritoneal dialysis. Blood Purif. 2010; 29: 137-144.
  24. Gotch F.A., Panlilio F., Sergeyeva O. et al. A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif. 2003; 21: 51-57.
  25. Lindsay R.M., Al-Hejaili F., Nesrallah G. Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis. 2003; 42, I[Suppl 1]: S24-S29.
  26. Daugirdas J.T., Chertow G.M., Larive B. et al. Effect of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol. 2012; 23: 727-738.
  27. Dusso A.S., Thadhani R, Slatopolsky E. Vitamin D receptor and analogs. Semin Nephrol. 2004; 24(1): 10-16.
  28. Martin K.J., Gonzalez E.A. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol. 2004; 24(5): 456-459.
  29. Lindberg J, Martin K.J., Gonzales E.A. A long-term, multicenter study of the efficacy and safety of paricalcitol in the end-stage renal disease. Clin Nephrol. 56(4): 315-323.
  30. Llach F., Yudd M. Paricalcitol in dialysis patients with end-stage renal disease: A century-old phenomenon. Kidney Int. 2002 (82): 73-80.
  31. Sprague S.M. Llach F., Amdahl M. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63(4): 1483-1490.
  32. Teng M., Wolf M., Ofsthum M.N. Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study 10.1681/ASN.2004070573. J Am Soc Nephrol. 2005; 16(4): 1115-25.
  33. Wu-Wong J.R., Tian J., Nakane M. Cardiovascular disease in chronic kidney failure: the role VDR activators. Curr Opin Investig Drugs. 2006; 7(3): 2006-213.
  34. Шутов Е.В., Лашутин С.В., Люосев В.С. и др. Новые возможности в лечении вторичного гиперпаратиреоза при комбинированной терапии цинакальцетом и малыми дозами активного метаболита витамина D. Клиническая нефрология. 2011; 5; 41-46.
  35. Smajilovic S., Sheykhzade M., Holmegard H.M. Calcimimetic, AMG 073, induces relaxation on isolated rat aorta. Vascul Pharmacol. 2007; 47(4): 222-228.
  36. Janssen M.J.A., van der Kuy A., Ter Wee P.M., Van Boven W.L.P. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol.; 1996; 45: 111-119.
  37. Михайлова Н.А. Магнийсодержащие фосфатбиндеры: новые терапевтические возможности при хронической болезни почек. Клиническая нефрология. 2013; 4: 47-52.
  38. Смирнов А.В., Волков М.М., Добронравов В.А. и др. Фосфорно-кальциевый обмен и состояние сердечно-сосудистой системы у пациентов с ранними стадиями хронической болезни почек. Тер. Арх. 2010; 6:25-28.
  39. Block G.A., Wheeler D.C., Persky M.S. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23: 1407-1415.
  40. Chertow G.M, Raggi P., McCarthy J.T. et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2003; 23: 307-314.
  41. Chertow G.M, Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
  42. Sadek T., Mazouz H., Bahloul H. et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant. 2003; 18: 582-588.
  43. Braun J., Asmus H.G., Holzer H. et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004; 62: 104-115.
  44. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
  45. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-441.
  46. Russo D., Miranda I., Ruocco C. et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007; 72: 1255-1261.
  47. Borzecki AM., Lee A, Wang S. W. et al. Survival in end stage renal disease: calcium carbonate vs sevelamer. J Clin Pharm Ther. 2007; 32: 617-624.
  48. Barreto D.V., Barreto Fd.C., de Carvalho A.B. et al. Phosphate binder impact on клиническая нефрология I - 2014 bone remodeling and coronary calcification-results from the BRiC study. Nephron. 2008; 110: 273-283.
  49. Qunibi W., Moustafa M., Muenz L.R. et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcifi cation in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008; 51: 952-965.
  50. Suki W.N., for the Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr. 2008; 18: 91-98.
  51. Takei T., Otsubo S., Uchida K. et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron. 2008; 108: 278-283.
  52. Wilson R., Zhang P., Smyth M. et al. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin. 2009; 25: 3021-3028.
  53. Panichi V., Bigazzi R., Paoletti S. et al. Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study. J Nephrol. 2010; 23:556-562.
  54. Shantouf R., Ahmadi N., Flores F. et al. Impact of phosphate binder type on coronary artery calcifi cation in hemodialysis patients. Clin Nephrol. 2010; 74: 12-18.
  55. Jean G., Lataillade D., Genet L. et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int. 2011; 15: 485-492.
  56. Kakuta T., Tanaka R., Hyodo T. et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcifi cation and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011; 57: 422-431.
  57. Toussaint N.D., Lau K.K., Polkinghorne K.R. et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton). 2011; 16: 290-298.
  58. Di Iorio B., Bellasi A., Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012; 7: 487-493.
  59. Navaneethan S.D. et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009; 54: 619-637.
  60. Jamal S.A., Fitchett D., Lok C.E. et al. The effects of calcium-based versus noncalcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009; 24: 3168-3174.
  61. Jamal S.A., Vandermeer B., Ragg P. et al. Effect of calcium-based versus noncalcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Published Online July 19, 2013 http://dx.doi.org/10.1016/ S0140-6736(13)60897-1.
  62. Moher D., Liberati A., Tetzlaff J. et al. for the PRISMA group. Preferred reporting items for systematic reviews and meta-analyses; the PRISMA statement. Ann Intern Med. 2009; 151: 264-269.
  63. Di Iorio B., Nargi O., Cucciniello E. et al. Coronary artery calcification progression is associated with arterial stiffness and cardiac repolarization deterioration in hemodialysis patients. Kidney Blood Press Res. 2011; 34: 180-187.
  64. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions, version 5.0.2. Chichester, West Sussex: The Cochrane Collaboration and John Wiley & Sons, 2008.
  65. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
  66. Di Iorio B., Molony D., Bell C. et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013 Oct; 62(4): 771-778.
  67. Земченков А.Ю. Герасимчук Р.П., Вишневский К.А. и др. Гиперфосфатемия у пациентов с хронической болезнью почек на диализе: риски и возможности коррекции. Клиническая нефрология. 2013; 4; 13-20.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies